Review Article

Role of Imaging in Cardiomyopathies

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image

  • Views: 1821

  • Likes: 1

  • Downloads: 245

  • Citations: 3

  • Read time: 18m
Average (ratings)
No ratings
Your rating

Abstract

Imaging has a central role in the diagnosis, classification, and clinical management of cardiomyopathies. While echocardiography is the first-line technique, given its wide availability and safety, advanced imaging, including cardiovascular magnetic resonance (CMR), nuclear medicine and CT, is increasingly needed to refine the diagnosis or guide therapeutic decision-making. In selected cases, such as in transthyretin-related cardiac amyloidosis or in arrhythmogenic cardiomyopathy, the demonstration of histological features of the disease can be avoided when typical findings are observed at bone-tracer scintigraphy or CMR, respectively. Findings from imaging techniques should always be integrated with data from the clinical, electrocardiographic, biomarker, genetic and functional evaluation to pursue an individualised approach to patients with cardiomyopathy.

Keywords

Imaging, cardiomyopathies, echocardiography, cardiac magnetic resonance, nuclear medicine,

Disclosure:The authors have no conflicts of interest to declare.

Received:

Accepted:

Published online:

DOI:https://doi.org/10.15420/cfr.2022.26

Correspondence Details:Giuseppe Vergaro, Scuola Superiore Sant’Anna and Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1 56124 Pisa, Italy. E: giuseppe1.vergaro@santannapisa.it

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Imaging and Cardiomyopathy Phenotype

Cardiomyopathies (CMPs) are a group of diseases affecting the cardiac muscle, heterogeneous in terms of aetiology and clinical presentation. In 2008, a European Society of Cardiology (ESC) position statement defined CMPs as myocardial disorders “in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality”.1

CMPs were grouped into specific morphological and functional phenotypes (hypertrophic, dilated, arrhythmogenic, restrictive, or other CMPs), and each phenotype was sub-classified into familial/genetic and non-familial/non-genetic forms.1 CMPs present variable expressions and symptoms, which may change over time.

CMPs may represent a challenge for cardiologists and imaging specialists, but an in-depth knowledge of aetiologies and characteristic features can lead to the correct diagnosis. The diagnostic workup of patients with suspected CMP includes clinical history and physical examination, a 12-lead ECG, specific laboratory tests, and often an endomyocardial biopsy and genetic testing. Cardiac imaging plays a pivotal role in the diagnosis of CMPs and their differentiation from mimicking conditions, such as athlete’s heart. Transthoracic echocardiography (TTE) is a safe, readily available technique that may raise the suspicion of CMP or allow a first assessment of patients with suspected CMP. Other imaging modalities, such as cardiac magnetic resonance (CMR), cardiac CT (CCT) and nuclear imaging, may help come to the correct diagnosis. In some cases, imaging findings alone are sufficient to diagnose specific disorders with no need for histological demonstration. The most notable case is amyloid transthyretin (ATTR) cardiac amyloidosis (CA), which can be diagnosed when there is an intense myocardial uptake of bone tracers on scintigraphy, and no monoclonal protein is found.2

Besides aetiological diagnosis, imaging techniques may help detect cardiac involvement in an earlier stage, characterise the remodelling pattern, perform an accurate functional assessment and risk stratification, and finally guide therapeutic decisions. TTE also offers the possibility of serial examinations over time. When possible, basic TTE examination should be integrated by speckle-tracking imaging of the left ventricle (LV), and, ideally, also of other cardiac chambers. CMR provides additional anatomical and functional information and enables tissue characterisation, which has important prognostic implications. Other techniques, such as CCT, scintigraphy or PET, may provide additional information to predict future disease trajectories and guide patient management.3 Table 1 provides an overview of the utility of different imaging modalities for the assessment of CMPs.

Utility of Different Imaging Modalities for the Assessment of Cardiomyopathies

Article image
Download

Overall, multimodality cardiac imaging plays an important role in clinical decision-making and helps to improve patients’ management and outcomes. In this review, we provide an overview of the current applications and some future perspectives on the use of imaging techniques in the diagnosis and treatment of patients with CMPs.

3D Echocardiography

3D echocardiography provides real-time images of the heart in motion that can be displayed at full or cropped volume, allows a more accurate study of cardiac geometry (LV and RV volumes, LV mass) and function (LV and RV ejection fraction, LV regional wall motion, dyssynchrony, and dyssynchrony index). Measurements of linear dimensions and areas can be based on 3D-guided 2D, which ensures higher accuracy than 2D measurements, or on volumetric rendered images that highly depend on image processing.7

Speckle Tracking Echocardiography

Speckle tracking echocardiography (STE) enables the calculation of motion, velocity, strain and strain rate by identifying a specific image feature, following it frame after frame, and analysing its displacement over time. Good image quality is necessary for STE.7 Global longitudinal strain (GLS) is one of the most studied parameters to detect preclinical disease, especially in DCM.17 Studies on HCM have focused on LA peak strain during the reservoir phase, corresponding to LV systole, while in ACM RV GLS can be calculated by averaging RV peak systolic longitudinal strain values from six RV segments.12,18 Conversely, RV free wall longitudinal strain is to be preferred to RV GLS in takotsubo syndrome.19 In patients with suspected CA, peak LA longitudinal strain and peak atrial contraction strain have independent diagnostic value (Figure 1).20 LV and RV strain, as well as LA enlargement, RV dilatation and RV contractile dysfunction, are important prognostic markers in DCM.7 Longitudinal myocardial function can be studied also in cardiac sarcoidosis with 2D STE or TDI-derived strain, allowing the identification of the disease at early stages, when other 2D echo features may be absent.21

Figure 1: Echocardiography in Cardiac Amyloidosis

Article image
Download

Stress Echocardiography

Stress echocardiography dynamically evaluates myocardial structure and function under a stress condition induced by physical exercise (using a treadmill or a bicycle) or a pharmacological agent (inotrope or vasodilator). Images are acquired at baseline, at a low workload and at peak exercise.7 Myocardial contractile reserve, studied with stress echocardiography, helps distinguish ischaemic from non-ischaemic disease and holds prognostic importance.22,23 Moreover, a limited coronary flow and a reduced or absent contractile reserve are often present in subclinical

CMPs.24–26 Exercise echocardiography is used to quantify mitral regurgitation and to study inducible LVOTO (which is typically increased at the beginning of the recovery phase) in HCM patients.24

Cardiac Magnetic Resonance

CMR is a multi-parametric, highly reproducible, non-invasive imaging technique with a relatively high spatial, temporal and contrast resolution, which has become an essential tool for the evaluation of CMPs. Indeed, CMR allows not only the quantification of biventricular volumes, mass, wall thickness, systolic- and diastolic function, intra- and extracardiac flows, but also the detection of myocardial oedema, fibrosis, and the accumulation of other intra/extracellular substances (such as fat, iron, or amyloid), thus providing unique information for disease characterisation.27,28 It has only a few contraindications, mostly related to MR-unsafe metal implants, severe renal dysfunction (which limits the use of several gadolinium-based contrast agents), patient discomfort (claustrophobia), tachyarrhythmias or poor breath-holding ability (which might significantly degrade image quality).29

Figure 2: Cardiac Magnetic Resonance in Dilated Cardiomyopathy Left Ventricular Dilation in a Patient with Dilated Cardiomyopathy

Article image
Download

In patients with non-ischemic DCM, CMR is the gold standard technique for the quantification of biventricular volumes, mass, and EF with cine steady-state free-precession (SSFP) sequences, and for the assessment of myocardial fibrosis with late gadolinium enhancement (LGE) sequences.30 LGE can be found in about 30–50% of DCM patients, typically in a patchy, midwall or subepicardial distribution (Figure 2). Since the first study by Assomull et al. in 2006, midwall fibrosis detected by LGE has emerged as a predictor of adverse prognosis, including all-cause and cardiovascular mortality, sudden cardiac death (SCD), appropriate ICD therapy and ventricular arrhythmias (VA), independently from left ventricular ejection fraction (LVEF).31–33 Interestingly, while the relationship between LVEF and VA or SCD is weak in DCM patients, a strong, significant association has been demonstrated between LGE and VA or SCD, even in patients with LVEF >35%. Different LGE location, pattern or extent have different prognostic impacts, although further larger investigations are needed.34,35 The absence of LGE predicts the occurrence of reverse remodelling, while the presence and transmural pattern of LGE in the LV lateral wall predicts a poor response to cardiac resynchronisation therapy (CRT).36–39 Native myocardial T1 and extracellular volume (ECV) mapping track myocardial fibrosis and interstitial remodelling, and have recently emerged as independent markers of poor outcome.40–42 Recently, GLS measured by feature-tracking analysis of cine SSFP images was found to correlate better than LVEF and B-type natriuretic peptide with the composite outcome of cardiac death, heart transplantation and appropriate ICD shock.43 CMR plays a crucial role also in the detection of LV noncompaction (LVNC), whose diagnosis is particularly challenging, especially due to the overlap with other CMPs and normal LV trabeculation. Besides several geometric diagnostic criteria with limited diagnostic and prognostic utility, the most powerful prognostic parameters in LVNC are the presence of LV systolic dysfunction and LGE.44–48

Figure 3: Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy Disproportionate Apical Hypertrophy in a Patient with Hypertrophic Cardiomyopathy

Article image
Download

In patients with HCM, CMR allows the morphological assessment of cardiac chambers, including unusual patterns of hypertrophy (lateral, apical or RV distribution), myocardial crypts, papillary muscle abnormalities, elongated mitral valve leaflets and apical aneurysms, which are not always easily visualised by echocardiography.49–52 Myocardial fibrosis detected by LGE imaging is a common finding in HCM, occurring in up to 80% of patients (Figure 3), so that only LGE extent is predictive of outcome: an LGE threshold of 10–15% of the LV mass identifies patients at high risk of VA, even in the absence of other major risk factors, and has been listed among the criteria to be considered for the selection of patients to be referred for ICD in the recently updated American Heart Association/American College of Cardiology (AHA/ACC) guidelines.53–57 Even scar heterogeneity (expressed as ‘dispersion map of LGE’), scar channels (assessed with an advanced post-processing analysis to differentiate the scar core and the border zone of LGE images), longitudinal strain, myocardial oedema (assessed through T2-weighted imaging), native T1 and ECV mapping are emerging as prognostic markers in HCM patients.58–64

CMR is of utmost importance for the differential diagnosis of hypertrophic phenocopies. In particular, CA is characterised by diffuse subendocardial-to-transmural LGE with variable biventricular and biatrial involvement, which tracks amyloid deposition and patient prognosis: while only subtle LGE areas might be present in the very early disease stages, LGE imaging can be challenging in advanced stages, due to the diffuse nature of LGE and to the equalisation of myocardial and blood pool nulling point.65 An increased native T1 demonstrated high diagnostic accuracy in patients with suspected CA, but ECV represents the best parameter to assess amyloid burden, patient outcome and response to treatment.66–71

CMR holds strong potential for diagnostic, prognosis and therapeutic monitoring in Anderson-Fabry disease (AFD), particularly because intracellular glycosphingolipids accumulation causes a shortening of native T1, while ECV is normal compared to other CMPs characterised by interstitial infiltration.72

CMR represents an essential tool for the diagnosis and risk stratification of iron overload CMPs, including genetic haemochromatosis and hereditary anaemias: myocardial iron deposits reduce both T2* and native T1 relaxation times, thus allowing an accurate non-invasive diagnosis of cardiac siderosis and treatment monitoring.73,74

Figure 4: Cardiac Magnetic Resonance in Arrhythmogenic Cardiomyopathy Right Ventricular Arrhythmogenic Cardiomyopathy, Manifesting with Right Ventricular Free Wall Hypo/Akinesia

Article image
Download

ACM is a genetically determined heart muscle disease characterised by myocardial fibro-fatty replacement with variable RV and LV involvement, clinically associated with malignant ventricular arrhythmias and SCD.75 CMR has always been regarded as a tool for the non-invasive detection of major morpho-functional abnormalities (biventricular dilation, dysfunction and regional wall motion abnormalities) (Figure 4). In the recently published Padua criteria, CMR has gained further importance, with the inclusion of LGE as a major structural criterion besides endomyocardial biopsy.76 The presence of circumferential LV subepicardial LGE in short axis view (ring pattern) has been consistently reported in left-dominant forms with a specific genotype.77 Similarly to DCM, LV LGE identifies patients with a high arrhythmic risk who are candidates to ICD implantation regardless of the severity of systolic dysfunction.78 CMR can also detect myocardial fatty infiltration as hyperintense areas on T1- or proton density (PD)-weighted images, or as India ink artefacts at conventional cine-SSFP images, which nonetheless have limited sensitivity and specificity in the context of a low spatial resolution.79,80 T2-weighted images might allow the depiction of myocardial oedema in case of an ACM presentation with chest pain and troponin release, which might be encountered in paediatric

patients and carriers of DSP (desmoplakin) gene mutations with a clinical presentation similar to a recurrence of myocarditis.81,82

Nuclear Medicine

Nuclear medicine offers imaging tools to evaluate myocardial perfusion, innervation and metabolism induced by inflammatory processes as in myocarditis and cardiac sarcoidosis, or in CA. In the last decade, the use of specific single-photon emission CT (SPECT) radiopharmaceuticals has allowed the identification of the presence of ATTR-CA, while the use of new PET radiopharmaceuticals could help to achieve an early diagnosis of immunoglobulin light-chain (AL) CA without the need for biopsy confirmation.

Perfusion and Innervation SPECT Tracers

SPECT with tracers such as 201Tl, sestamibi or tetrofosmin labelled with 99mTc allows the exclusion of the presence of ischaemia, particularly in patients with HCM who present with chest pain or who have LV systolic dysfunction. Using dedicated software, it is possible to estimate the systolic and diastolic function of the LV from a myocardial perfusion study.83,84 In cardiac sarcoidosis, the assessment of LV contraction dyssynchrony by myocardial perfusion-gated SPECT can be useful for prognostic stratification; furthermore, the assessment of perfusion recovery after corticosteroid therapy seems to be associated with a lower risk of major adverse cardiac events.85,86

SPECT with 123I-labeled metaiodobenzylguanidine (MIBG) allows the evaluation of the integrity of myocardial adrenergic innervation. In AFD, the extent of impairment of adrenergic innervation correlates with the degree of fibrosis, but autonomic dysfunction appears to precede myocardial fibrosis, so the innervation scintigraphy could allow an earlier diagnosis of this disease.87 A reduction in the density of adrenergic endings has also been reported in CA, probably as a consequence of the toxic effect of the amyloid fibrils.88,89 The use of 123I-MIBG for the evaluation of adrenergic damage has also been described in patients with cardiac sarcoidosis, but it is not routinely adopted.90,91

PET Tracers Assessing Myocardial Inflammation

18F-labelled fluorodeoxyglucose (FDG) is the main radiopharmaceutical used in PET. Although its main use is oncological, it is not tumour-specific, and it allows the visualisation of areas of leukocyte infiltration during inflammatory processes. The degree of glucose uptake in the vital myocardium correlates directly with the circulating levels of insulin and inversely with the level of circulating free fatty acids, while the degree of glucose metabolism of the inflammatory tissue is relatively independent of insulin. For this reason, the use of 18F-FDG for the study of myocarditis requires an adequate dietary preparation that suppresses the myocardial glucose uptake.92–94 PET with 18F-FDG can be used to characterise the inflammatory response after acute myocardial infarction, to assess the extent of the disease and the response to therapy in the case of myocarditis and in sarcoidosis.95–98 Lymphocytes involved in the granulomatous process of sarcoidosis express membrane receptors for somatostatin; new PET radiopharmaceuticals with an affinity for somatostatin receptors, such as the peptides DOTATOC, DOTATATE and DOTANOC labelled with 68Ga, have been shown to have a greater diagnostic accuracy than 18F-FDG for cardiac sarcoidosis.99

Nuclear Medicine in Cardiac Amyloidosis

Some SPECT tracers originally developed to study bone metabolism and labelled with 99mTc have been successfully used to identify ATTR-CA. 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) cardiac uptake in patients with ATTR-CA has been known since the 1970s; thanks to the evidence collected in the last 15 years, bone tracer scintigraphy has been a fundamental tool in the diagnostic path of patients with suspected ATTR-CA.100 18F-NaF is a PET radiopharmaceutical for bone imaging that also accumulates in myocardial ATTR deposits.101,102 However, a lower sensitivity of PET compared to scintigraphy has been reported.103,104 In the last decade, PET radiopharmaceuticals developed for brain amyloid substance have shown binding affinity also for myocardial amyloid, both in the context of a systemic amyloidosis with cardiac involvement and in the case of isolated CA.105–110 The most promising of these tracers is 18F-florbetaben, which has proven able not only to identify CA, but also to discriminate between AL-CA and other mimicking conditions and to evaluate the response to therapy (Figure 5).111,112

Figure 5: Nuclear Medicine in Cardiac Amyloidosis Scans from 18F-Florbetaben PET and from 99mTc-HDP Scintigraphy in a Patient with Light Chain Cardiac Amyloidosis

Article image
Download

Cardiac CT

The latest generation of CCT equipment, with the implementation of temporal resolution, the use of lower kV values, high volume coverage, iterative reconstruction algorithms and low radiation exposure, allows the assessment of ventricular and atrial size, morphology, function, density,

first pass perfusion defects and delayed-enhancement pattern in sub-millimetric multiplanar reconstructions with a short acquisition time.113 In the setting of CMPs, pre-contrast CCT can easily depict myocardial areas with adipose density as well as calcifications. After contrast enhancement, in addition to providing information on the causes of ischaemia and on the risk of major cardiac events, CCT can qualitatively and quantitatively assess myocardial perfusion and the presence of myocardial muscle alterations, discriminating between ischaemic and non-ischemic aetiology, disclosing myocardial phenotype, the presence of fat, as well as complications such as intracavitary thrombosis.114,115 CCT may therefore be considered as an option in patients with contraindications to CMR or when coronary artery disease must be ruled out.116 Next challenges will concern the evaluation of myocardial metabolism with CCT photon counting and the assessment of myocardial oedema and fibrosis.117,118

Multimodality Imaging and Integration with Circulating Biomarkers

The integration of different imaging techniques may help overcome the different limitations and weaknesses of single techniques.17,119 For example, echocardiographic findings may be non-specific, therefore, have a limited role in identifying the underlying aetiology.119 CMR is generally performed after echocardiography and has a primary role in assessing the aetiology of CMPs.120 CMR findings, namely LGE and parametric imaging (T1 and T2 values), allow an accurate characterisation of myocardial tissue in terms of fibrosis, scar, inflammation, oedema, or infiltration.119,120 CCT is highly valuable to exclude significant epicardial coronary artery disease in DCM.17 Additionally, the good spatial resolution and ease of navigation make cardiac CCT an option in the presence of suboptimal echocardiographic findings and contraindications to CMR.17

The integration of imaging with circulating biomarkers allows an even more accurate characterisation of the different types of CMPs.121 For example, although the role of nuclear imaging is generally limited in the evaluation of patients with suspected CMPs, ATTR-CA is diagnosed with a 100% specificity in the presence of a positive bone scintigraphy combined with the absence of a monoclonal protein or abnormal light chains in blood samples.122 In addition, specific imaging markers provide additional information to biomarkers and refine risk prediction in AL-CA.123

Further research is required to integrate imaging findings from different techniques with clinical data and circulating biomarkers to create a multifactorial algorithm for the diagnosis and prognostic assessment, as well as for the individualisation of therapy in each specific CMP.119

Perspectives

The growing body of knowledge on the pathophysiology and natural history of CMPs, and the availability of disease-modifying therapies for some conditions have made early diagnosis more crucial than ever. However, some CMPs may show milder phenotypes in early disease stages, which can overlap between different diseases or even physiological conditions. Emblematic cases are represented by DCM versus ACM with prevalent LV involvement, or HCM versus athlete’s heart.17,124 The integration of additional information from different imaging modalities can maximise the diagnostic performance.17 For inherited CMPs with adolescent-onset, such as HCM and some forms of ACM, early diagnosis presents additional challenges, particularly for family screening. First, the diagnostic criteria have been mostly validated on adult subjects with well-differentiated phenotypes, therefore, their diagnostic performance at a younger age may be lower.125 Second, echocardiography is the preferred tool for screening, but is unable to identify subtler structural abnormalities, so it currently remains to be defined which methods and timing are the most appropriate for family screening of inherited CMPs. For example, the 2014 ESC guidelines on the diagnosis and management of HCM recommend clinical evaluation with ECG and echocardiography and long-term follow-up in first-degree relatives who have the same defined pathological mutation as the proband; when no definite genetic mutation is identified in the proband, ECG and echocardiography should be considered in first-degree adult relatives and repeated every 2–5 years (or 6–12 months if nondiagnostic abnormalities are present).126 Similar recommendations are provided by the 2020 AHA/ACC Guidelines, which also mention the possibility of employing CMR for family screening when echocardiography is inconclusive.57 As for ACM, the 2019 Heart Rhythm Society (HRS) expert consensus statement recommends clinical evaluation by ECG and cardiac imaging every 1–3 years starting at 10–12 years of age in first-degree relatives. However, the precise imaging technique to be employed is not specified.127

Another future perspective is the validation of new diagnostic methods and their integration into the diagnostic flow charts of CMPs. CMR mapping techniques have proven to be very reliable in supporting the diagnosis of CA and predicting prognosis, yet CMR currently has a secondary role in the diagnostic flow chart of CA proposed by the ESC.2 In many cases of suspected CMP, endomyocardial biopsy is still crucial.128 However, in the near future, new imaging tools might limit the need for endomyocardial biopsy in specific cases. For example, recent studies have shown that delayed cardiac uptake of 18F-florbetaben on PET/CT imaging is able to accurately discriminate AL-CA from either ATTR-CA or other phenocopies.111

Besides diagnosis, imaging tools can be used to highlight collateral structural abnormalities of some CMPs that might have clinical relevance. For example, it has been demonstrated that some forms of ACM, such as those caused by DSP mutations, can have a clinical course that passes through “hot phases” characterised by myocardial inflammation and the release of biomarkers of myocardial damage, which sometimes are misdiagnosed as acute myocarditis.81 These phases hold prognostic significance and can be identified both by CMR as the presence of oedema T2-weighted sequences and by 18F-FDG PET.124,129 Myocardial oedema detected through CMR can also be a hallmark of cardiac remodelling in HCM, and is associated with more advanced disease and increased arrhythmic load.61

Finally, the role of advanced imaging modalities in monitoring the response to therapy remains to be defined. One study on patients with ATTR-CA has demonstrated that serial ECV quantification by CMR can be used to monitor the effectiveness of reducing the cardiac amyloid burden by patisiran, a small interfering RNA able to knock down the expression of transthyretin in the liver.71 Similarly, it has been recently demonstrated that ECV quantification by CMR can be used to monitor cardiac amyloid regression following chemotherapy in AL amyloidosis. Notably, a deep haematologic response is not sufficient per se to grant cardiac amyloid regression, while changes in ECV over time independently predict prognosis, making it a unique marker of treatment response.130

Conclusion

Recent advances in cardiac imaging and its increased accessibility allow a precise assessment of ventricular dimension and function, as well as a non-invasive tissue characterisation of the myocardium. However, the growing knowledge from imaging studies should always be interpreted based on all clinical elements (i.e. clinical assessment, electrocardiographic findings, biomarkers, genetic and functional assessment). While echocardiography remains the first-line imaging tool for the management of patients with CMP and can be implemented with advanced analyses (e.g. STE, stress echocardiography, contrast-enhanced echocardiography), CMR represents the gold standard technique for myocardial anatomy and tissue characterisation, including novel tools (e.g. T1/T2/T2*/ECV mapping, quantitative perfusion, diffusion tension imaging and feature tracking). An integrated clinical and imaging approach seems essential to characterise the CMP phenotype and identify the underlying aetiologies, to predict disease prognosis and to ensure a tailored therapeutic management.

References

  1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270–6.
    Crossref | Pubmed
  2. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2021;23:512–26.
    Crossref | PubMed
  3. Casas G, Rodríguez-Palomares JF. Multimodality cardiac imaging in cardiomyopathies: from diagnosis to prognosis. J Clin Med 2022;11:578.
    Crossref | PubMed
  4. Rankin K, Thampinathan B, Thavendiranathan P. Imaging-specific cardiomyopathies a practical guide. Heart Fail Clin 2019;15:275–95.
    Crossref | PubMed
  5. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;16:280.
    Crossref | PubMed
  6. Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2022;35:533–69.
    Crossref | PubMed
  7. Lancellotti P, Cosyns B, eds. The EACVI echo handbook. Oxford: Oxford University Press, 2016.
    PubMed
  8. Chockalingam A, Xie GY, Dellsperger KC. Echocardiography in stress cardiomyopathy and acute LVOT obstruction. Int J Cardiovasc Imaging 2010;26:527–35.
    Crossref | PubMed
  9. Cortigiani L, Rigo F, Gherardi S, et al. Prognostic implications of coronary flow reserve on left anterior descending coronary artery in hypertrophic cardiomyopathy. Am J Cardiol 2008;102:1718–23.
    Crossref | PubMed
  10. Habib G, Bucciarelli-Ducci C, Caforio ALP, et al. Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document in collaboration with the “Working Group on Myocardial and Pericardial Diseases” of the European Society of Cardiology endorsed by the Indian Academy of Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:1090–121.
    Crossref | PubMed
  11. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314.
    Crossref | PubMed
  12. Haugaa KH, Basso C, Badano LP, et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy – an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:237–53.
    Crossref | PubMed
  13. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J 2010;31:806–14.
    Crossref | PubMed
  14. Mansencal N, Pellerin D, Lamar A, et al. Diagnostic value of contrast echocardiography in Tako-Tsubo cardiomyopathy. Arch Cardiovasc Dis 2010;103:447–53.
    Crossref | PubMed
  15. Nunes MCP, Badano LP, Marin-Neto JA, et al. Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging 2018;19:459–460n.
    Crossref | PubMed
  16. Viotti RJ, Vigliano C, Laucella S, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 2004;90:655–60.
    Crossref | PubMed
  17. Donal E, Delgado V, Bucciarelli-Ducci C, et al. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2019;20:1075–93.
    Crossref | PubMed
  18. Paraskevaidis IA, Panou F, Papadopoulos C, et al. Evaluation of left atrial longitudinal function in patients with hypertrophic cardiomyopathy: a tissue Doppler imaging and two-dimensional strain study. Heart 2009;95:483–9.
    Crossref | PubMed
  19. Heggemann F, Hamm K, Brade J, et al. Right ventricular function quantification in takotsubo cardiomyopathy using two-dimensional strain echocardiography. PLoS One 2014;9:e103717.
    Crossref | PubMed
  20. Aimo A, Fabiani I, Giannoni A, et al. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2022;24:130–41.
    Crossref | PubMed
  21. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine. Eur Heart J Cardiovasc Imaging 2017;18:1073–89.
    Crossref | PubMed
  22. Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement – executive summary. Eur Heart J 2009;30:278–89.
    Crossref | PubMed
  23. Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007;20:1021–41.
    Crossref | PubMed
  24. Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008;9:415–37.
    Crossref | PubMed
  25. Naqvi TZ, Goel RK, Forrester JS, Siegel RJ. Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999;34:1537–44.
    Crossref | PubMed
  26. Lee JH, Yang DH, Choi WS, et al. Prediction of improvement in cardiac function by high dose dobutamine stress echocardiography in patients with recent onset idiopathic dilated cardiomyopathy. Int J Cardiol 2013;167:1649–50.
    Crossref | PubMed
  27. Grigoratos C, Todiere G, Barison A, Aquaro GD. The role of MRI in prognostic stratification of cardiomyopathies. Curr Cardiol Rep 2020;22:61.
    Crossref | PubMed
  28. Merlo M, Gagno G, Baritussio A, et al. Clinical application of CMR in cardiomyopathies: evolving concepts and techniques: a position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology. Heart Fail Rev 2023;28:77–95.
    Crossref | PubMed
  29. Barison A, Baritussio A, Cipriani A, et al. Cardiovascular magnetic resonance: what clinicians should know about safety and contraindications. Int J Cardiol 2021;331:322–8.
    Crossref | PubMed
  30. Barison A, Grigoratos C, Todiere G, Aquaro GD. Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance. Heart Fail Rev 2015;20:731–49.
    Crossref | PubMed
  31. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977–85.
    Crossref | PubMed
  32. Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy. JACC Heart Fail 2017;5:28–38.
    Crossref | PubMed
  33. Guaricci AI, Masci PG, Muscogiuri G, et al. Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy in non-ischaemic dilated cardiomyopathy: an international registry. Europace 2021;23:1072–83.
    Crossref | PubMed
  34. Halliday BP, Baksi AJ, Gulati A, et al. Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement. JACC Cardiovasc Imaging 2019;12:1645–55.
    Crossref | PubMed
  35. Barison A, Aimo A, Mirizzi G, et al. The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. Int J Cardiol 2020;307:180–6.
    Crossref | PubMed
  36. Ikeda Y, Inomata T, Fujita T, et al. Cardiac fibrosis detected by magnetic resonance imaging on predicting time course diversity of left ventricular reverse remodeling in patients with idiopathic dilated cardiomyopathy. Heart Vessels 2016;31:1817–25.
    Crossref | PubMed
  37. Barison A, Aimo A, Ortalda A, et al. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol 2018;250:195–200.
    Crossref | PubMed
  38. Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011;13:29.
    Crossref | PubMed
  39. Taylor RJ, Umar F, Panting JR, et al. Left ventricular lead position, mechanical activation, and myocardial scar in relation to left ventricular reverse remodeling and clinical outcomes after cardiac resynchronization therapy: a feature-tracking and contrast-enhanced cardiovascular magnetic resonance study. Heart Rhythm 2016;13:481–9.
    Crossref | PubMed
  40. Puntmann VO, Carr-White G, Jabbour A, et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. JACC Cardiovasc Imaging 2016;9:40–50.
    Crossref | PubMed
  41. Barison A, Del Torto A, Chiappino S, et al. Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown) 2015;16:681–7.
    Crossref | PubMed
  42. Vita T, Gräni C, Abbasi SA, et al. Comparing CMR mapping methods and myocardial patterns toward heart failure outcomes in nonischemic dilated cardiomyopathy. JACC Cardiovasc Imaging 2019;12:1659–69.
    Crossref | PubMed
  43. Buss SJ, Breuninger K, Lehrke S, et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 2015;16:307–15.
    Crossref | PubMed
  44. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2005;46:101–5.
    Crossref | PubMed
  45. Jacquier A, Thuny F, Jop B, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 2010;31:1098–104.
    Crossref | PubMed
  46. Grothoff M, Pachowsky M, Hoffmann J, et al. Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. Eur Radiol 2012;22:2699–709.
    Crossref | PubMed
  47. Grigoratos C, Barison A, Ivanov A, et al. Meta-analysis of the prognostic role of late gadolinium enhancement and global systolic impairment in left ventricular noncompaction. JACC Cardiovasc Imaging 2019;12:2141–51.
    Crossref | PubMed
  48. Macaione F, Meloni A, Positano V, et al. The prognostic role of CMR using global planimetric criteria in patients with excessive left ventricular trabeculation. Eur Radiol 2021;31:7553–65.
    Crossref | PubMed
  49. Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2017;10:e005372.
    Crossref | PubMed
  50. Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008;101:668–73.
    Crossref | PubMed
  51. Captur G, Lopes LR, Mohun TJ, et al. Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2014;7:863–71.
    Crossref | PubMed
  52. Reant P, Captur G, Mirabel M, et al. Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2015;17:64.
    Crossref | PubMed
  53. Aquaro GD, Masci P, Formisano F, et al. Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. Am J Cardiol 2010;105:392–7.
    Crossref | PubMed
  54. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484–95.
    Crossref | PubMed
  55. Todiere G, Nugara C, Gentile G, et al. Prognostic role of late gadolinium enhancement in patients with hypertrophic cardiomyopathy and low-to-intermediate sudden cardiac death risk score. Am J Cardiol 2019;124:1286–92.
    Crossref | PubMed
  56. Freitas P, Ferreira AM, Arteaga-Fernández E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson 2019;21:50.
    Crossref | PubMed
  57. Ommen SR, Mital S, Burke MA, et al. AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2020;76:3022–55.
    Crossref | PubMed
  58. Aquaro GD, Grigoratos C, Bracco A, et al. Late gadolinium enhancement–dispersion mapping: a new magnetic resonance imaging technique to assess prognosis in patients with hypertrophic cardiomyopathy and low-intermediate 5-year risk of sudden death. Circ Cardiovasc Imaging 2020;13:e010489.
    Crossref | PubMed
  59. Sánchez-Somonte P, Quinto L, Garre P, et al. Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm 2021;18:1336–43.
    Crossref | PubMed
  60. Negri F, Muser D, Driussi M, et al. Prognostic role of global longitudinal strain by feature tracking in patients with hypertrophic cardiomyopathy: the STRAIN-HCM study. Int J Cardiol 2021;345:61–7.
    Crossref | PubMed
  61. Todiere G, Pisciella L, Barison A, et al. Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability. PLoS One 2014;9:e111366.
    Crossref | PubMed
  62. Avanesov M, Münch J, Weinrich J, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol 2017;27:5136–45.
    Crossref | PubMed
  63. Li Y, Liu X, Yang F, et al. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy. Eur Radiol 2021;31:4557–67.
    Crossref | PubMed
  64. Treibel TA, Fridman Y, Bering P, et al. Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1. JACC Cardiovasc Imaging 2020;13:44–54.
    Crossref | PubMed
  65. Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 2020;13:1368–83.
    Crossref | PubMed
  66. Baggiano A, Boldrini M, Martinez-Naharro A, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:69–80.
    Crossref | PubMed
  67. Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 2020;13:1299–310.
    Crossref | PubMed
  68. Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015;36:244–51.
    Crossref | PubMed
  69. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 2017;70:466–77.
    Crossref | PubMed
  70. Martinez-Naharro A, Abdel-Gadir A, Treibel TA, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging 2018;11:152–4.
    Crossref | PubMed
  71. Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 2021;14:189–99.
    Crossref | PubMed
  72. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392–8.
    Crossref | PubMed
  73. Sado DM, Maestrini V, Piechnik SK, et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging 2015;41:1505–11.
    Crossref | PubMed
  74. Meloni A, Martini N, Positano V, et al. Myocardial iron overload by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach that correlates with cardiac complications. J Cardiovasc Magn Reson 2021;23:70.
    Crossref | PubMed
  75. Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res 2017;121:784–802.
    Crossref | PubMed
  76. Corrado D, Perazzolo Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020;319:106–14.
    Crossref | PubMed
  77. Augusto JB, Eiros R, Nakou E, et al. Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging 2020;21:326–36.
    Crossref | PubMed
  78. Aquaro GD, De Luca A, Cappelletto C, et al. Prognostic value of magnetic resonance phenotype in patients with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2020;75:2753–65.
    Crossref | PubMed
  79. Aquaro GD, Barison A, Todiere G, et al. Usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2016;118:1730–6.
    Crossref | PubMed
  80. Tandri H, Castillo E, Ferrari VA, et al. Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. J Am Coll Cardiol 2006;48:2277–84.
    Crossref | PubMed
  81. Bariani R, Cipriani A, Rizzo S, et al. ‘Hot phase’ clinical presentation in arrhythmogenic cardiomyopathy. Europace 2021;23:907–17.
    Crossref | PubMed
  82. Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 2020;141:1872–84.
    Crossref | PubMed
  83. Germano G, Kiat H, Kavanagh PB, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138–47.
    PubMed
  84. Gimelli A, Liga R, Pasanisi EM, et al. Evaluation of left ventricular diastolic function with a dedicated cadmium-zinc-telluride cardiac camera: comparison with Doppler echocardiography. Eur Heart J Cardiovasc Imaging 2014;15:972–9.
    Crossref | PubMed
  85. Koyanagawa K, Naya M, AIkawa T, et al. Prognostic value of phase analysis on gated single photon emission computed tomography in patients with cardiac sarcoidosis. J Nucl Cardiol 2021;28:128–36.
    Crossref | PubMed
  86. Koyanagawa K, Naya M, AIkawa T, et al. The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction. J Nucl Cardiol 2021;28:1745–56.
    Crossref | PubMed
  87. Imbriaco M, Pellegrino T, Piscopo V, et al. Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging 2017;44:2266–73.
    Crossref | PubMed
  88. Gimelli A, Aimo A, Vergaro G, et al. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. Amyloid 2020;27:237–43.
    Crossref | PubMed
  89. Noordzij W, Glaudemans AWJM, van Rheenen RWJ, et al. 123I-labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:1609–17.
    Crossref | PubMed
  90. Hoitsma E, Faber CG, Van Kroonenburgh MJ, et al. Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:43–50.
    PubMed
  91. Imai E, Kaminaga T, Takada K, et al. Radioactive defect on I-123 MIBG myocardial SPECT imaging in a patient with cardiac sarcoidosis. Clin Nucl Med 2002;27:729–30.
    Crossref | PubMed
  92. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120–7.
    Crossref | PubMed
  93. Osborne MT, Hulten EA, Murthy VL, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol 2017;24:86–99.
    Crossref | PubMed
  94. Kobayashi Y, Kumita S, Fukushima Y, et al. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314–9.
    Crossref | PubMed
  95. Wollenweber T, Roentgen P, Schäfer A, et al. Characterizing the inflammatory tissue response to acute myocardial infarction by clinical multimodality noninvasive imaging. Circ Cardiovasc Imaging 2014;7:811–8.
    Crossref | PubMed
  96. Moriwaki K, Dohi K, Omori T, et al. A survival case of fulminant right-side dominant eosinophilic myocarditis. Int Heart J 2017;58:459–62.
    Crossref | PubMed
  97. Nensa F, Kloth J, Tezgah E, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl Cardiol 2018;25:785–94.
    Crossref | PubMed
  98. Ning N, Guo HH, Iagaru A, et al. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J Card Fail 2019;25:307–11.
    Crossref | PubMed
  99. Saric P, Young KA, Rodriguez-Porcel M, Chareonthaitawee P. PET imaging in cardiac sarcoidosis: a narrative review with focus on novel PET tracers. Pharmaceuticals (Basel) 2021;14:1286.
    Crossref | PubMed
  100. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2 – evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065–123.
    Crossref | PubMed
  101. Trivieri MG, Dweck MR, Abgral R, et al. 18F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol 2016;68:2712–4.
    Crossref | PubMed
  102. Morgenstern R, Yeh R, Castano A, et al. 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol 2018;25:1559–67.
    Crossref | PubMed
  103. Ng QKT, Sethi P, Saunders TA, et al. Discordant findings on 18F-NaF and 99mTc-HDP bone scans in a patient with ATTR cardiac amyloidosis. Clin Nucl Med 2018;43:e89–92.
    Crossref | PubMed
  104. Zhang LX, Martineau P, Finnerty V, et al. Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis. J Nucl Cardiol 2022;29:1132–40.
    Crossref | PubMed
  105. Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652–62.
    Crossref | PubMed
  106. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319–29.
    Crossref | PubMed
  107. Lhommel R, Sempoux C, Ivanoiu A, et al. Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis? Clin Nucl Med 2014;39:747–9.
    Crossref | PubMed
  108. Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography. Ann Nucl Med 2019;33:624–8.
    Crossref | PubMed
  109. Möckelind S, Axelsson J, Pilebro B, et al. Quantification of cardiac amyloid with [18F]flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid 2020;27:191–9.
    Crossref | PubMed
  110. Law WP, Wang WY, Moore PT, et al. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med 2016;57:1733–9.
    Crossref | PubMed
  111. Genovesi D, Vergaro G, Giorgetti A, et al. Florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging 2021;14:246–55.
    Crossref | PubMed
  112. Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with 18F-florbetaben-PET/CT in comparison to echocardiography, cardiac MRI ad DPD-scintigraphy. Eur J Nucl Med Mol Imaging 2019;46:1407–16.
    Crossref | PubMed
  113. Cademartiri F, Clemente A, Nistri S, Maffei E. Cardiac computed tomography as a complete functional tool. Eur Heart J Cardiovasc Imaging 2022;23:485–6.
    Crossref | PubMed
  114. Seitun S, Clemente A, De Lorenzi C, et al. Cardiac CT perfusion and FFRCTA: pathophysiological features in ischemic heart disease. Cardiovasc Diagn Ther 2020;10:1954–78.
    Crossref | PubMed
  115. Aziz W, Claridge S, Ntalas I, et al. Emerging role of cardiac computed tomography in heart failure. ESC Heart Fail 2019;6:909–20.
    Crossref | PubMed
  116. Lee HJ, Im DJ, Youn JC, et al. Assessment of myocardial delayed enhancement with cardiac computed tomography in cardiomyopathies: a prospective comparison with delayed enhancement cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 2017;33:577–84.
    Crossref | PubMed
  117. Dewey M, Siebes M, Kachelrieß M, et al. Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. Nat Rev Cardiol 2020;17:427–50.
    Crossref | PubMed
  118. Scully PR, Bastarrika G, Moon JC, Treibel TA. Myocardial extracellular volume quantification by cardiovascular magnetic resonance and computed tomography. Curr Cardiol Rep 2018;20:15.
    Crossref | PubMed
  119. Ederhy S, Mansencal N, Réant P, et al. Role of multimodality imaging in the diagnosis and management of cardiomyopathies. Arch Cardiovasc Dis 2019;112:615–29.
    Crossref | PubMed
  120. Mitropoulou P, Georgiopoulos G, Figliozzi S, et al. Multi-modality imaging in dilated cardiomyopathy: with a focus on the role of cardiac magnetic resonance. Front Cardiovasc Med 2020;7:97.
    Crossref | PubMed
  121. Schulz-Menger J, Maisch B, Abdel-Aty H, Pankuweit S. Integrated biomarkers in cardiomyopathies: cardiovascular magnetic resonance imaging combined with molecular and immunologic markers – a stepwise approach for diagnosis and treatment. Herz 2007;32:458–72.
    Crossref | PubMed
  122. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470–8.
    Crossref | PubMed
  123. Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2017;18:1057–64.
    Crossref | PubMed
  124. Galderisi M, Cardim N, D’Andrea A, et al. The multi-modality cardiac imaging approach to the athlete’s heart: an expert consensus of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:353.
    Crossref | PubMed
  125. Malik N, Mukherjee M, Wu KC, et al. Multimodality imaging in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Imaging 2022;15:e013725.
    Crossref | PubMed
  126. Authors/Task Force members, Elliott PM, Anastasakis A, et al.2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
    Crossref | PubMed
  127. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: executive summary. Heart Rhythm 2019;16:e373–407.
    Crossref | PubMed
  128. Porcari A, Baggio C, Fabris E, et al. Endomyocardial biopsy in the clinical context: current indications and challenging scenarios. Heart Fail Rev 2023;28:123–35.
    Crossref | PubMed
  129. Wang W, Murray B, Tichnell C, et al. Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. Europace 2022;24:268–77.
    Crossref | PubMed
  130. Protonotarios A, Wicks E, Ashworth M, et al. Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2019;284:99–104.
    Crossref | PubMed

Comments

You must be to comment. If you are not registered, you can register here.
Previous Volume Article Next Volume Article